ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026
Treatment of mpox with tecovirimat under expanded access use in the Central African Republic.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis programme primarily aimed to provide access to tecovirimat for patients with suspected mpox. Secondary objectives were to describe the clinical and virological features of Clade Ia mpox and assess the safety of tecovirimat. The programme also supported research capacity strengthening, improved case detection through surveillance engagement, and standardised case management.
methodsAn expanded access programme was implemented at Mbaiki District Hospital and Bangui General Hospital. Consenting patients with suspected mpox received oral tecovirimat for 14 days under a standardised protocol. Follow-up visits occurred at day 21 (if PCR-positive at day 14) and day 28 or later. Blood and lesion samples were collected at each visit.
resultsThirty-one patients were enrolled; 26 (84%) were PCR-positive and 24 (77%) had Clade Ia mpox. Symptoms were heterogeneous, most commonly lymphadenopathy, headache, myalgia, and active lesions. Most symptoms improved by day 14 and the final visit, though lymphadenopathy often persisted. PCR positivity declined over time but remained detectable in some cases. Six serious adverse events occurred in five patients.
conclusionsWhile no clear treatment benefit was demonstrated, the programme improved understanding of disease and strengthened clinical and research capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.